Tempus AI, Inc. (TEM) climbs after posting a strong Q3 revenue beat, swinging to adjusted EPS profit, and lifting 2026 revenue guidance. The rally reflects improved operating leverage, stronger growth across its core businesses, and renewed investor confidence in the company’s outlook.
Tempus AI, Inc. (TEM) climbed 12.03% after reporting a strong Q3 earnings beat, including $411.5 million in revenue and adjusted EPS of $0.07 versus expectations for a loss. The company also raised its 2026 revenue outlook, signaling improving execution and stronger confidence in its growth trajectory. For investors, the move reinforces the bullish case, but valuation and volatility remain key risks after the sharp rally.
Tempus AI, Inc. (TEM) climbs 12.03% to $80.91 at the 3 p.m. ET print on Nov. 2, 2026, while relative volume reaches 1.9x its 200-day average. The move follows a clear catalyst: Q3 revenue of $411.5M, an adjusted EPS beat, and a raised 2026 revenue outlook.
Key Takeaways
TEM climbed 12.03% to $80.91, with 1.9x relative volume and 12.72 million shares traded intraday.
Q3 revenue reached $411.5M, up 23% year over year, while adjusted EPS came in at $0.07 versus a $0.09 loss estimate.
Tempus raised 2026 revenue guidance to $1.60B to $1.605B from $1.59B and kept adjusted EBITDA guidance near $65M.
The business showed stronger operating leverage, with adjusted EBITDA rising to $25.6M and net loss narrowing to $14.9M.
The earnings reaction is positive, but a $14.34B market cap, -$1.44 EPS, and 3.54 beta keep valuation and volatility firmly in focus.
Why Tempus AI (TEM) Climbs Today: Q3 Earnings Beat and Guidance Raise
Tempus reported its third-quarter 2026 results before the open on Nov. 2. The company delivered $411.54M in revenue for the quarter ended September 2026, up 23.1% year over year. That figure topped the $411.34M consensus estimate by 0.05%.
The adjusted EPS result carried more weight. Tempus posted adjusted EPS of $0.07, compared with a consensus estimate for a $0.09 loss. The 177.78% earnings surprise gave traders a sharper profitability signal than revenue alone.
The company also raised full-year revenue guidance from $1.59B to a range of $1.60B to $1.605B. It kept adjusted EBITDA guidance near $65M. That combination supports the most likely catalyst for today's move: stronger execution paired with greater confidence in the full-year outlook.
Trading activity confirms a broad repricing rather than a thinly traded spike. Intraday volume reached 12.72 million shares, while relative volume stood at 1.9x the 200-day average. Needham also maintained a Buy rating and set an $89 price target on Nov. 2, reinforcing the positive tone after the results.
Tempus AI Financial Results Show Growth With Smaller Losses
Tempus delivered improvement across several operating measures. Gross profit rose to $266.7M, and gross margin expanded to 66% from 64% a year earlier. Oncology volume increased 32%, while Data & Applications revenue grew 33%.
Profitability also moved in the right direction. Adjusted EBITDA reached $25.6M, compared with $1.5M in the prior-year quarter. Net loss narrowed to $14.9M from $80.0M. Tempus still reported a GAAP loss of $0.08 per share, so the improvement does not erase the need for continued execution.
The guidance update gives investors a concrete forward benchmark. Tempus now expects roughly 25% annual revenue growth in 2026, while retaining its approximately $65M adjusted EBITDA target. The revenue increase is modest in absolute terms, but it confirms that management sees demand holding after a record quarter.
TEM Valuation, Data Moat, and Competitive Position
At the $80.91 print, Tempus carries a $14.34B market capitalization. The trailing EPS figure is -$1.44, which makes standard P/E analysis a poor fit. The more relevant valuation debate centers on whether 23% revenue growth and improving EBITDA justify the premium investors assign to the platform.
Tempus combines diagnostics, analytics, clinical applications, and a multimodal data repository. Its platform connects clinician workflows with laboratory testing and software tools. That structure gives the business two connected engines: diagnostics create data, while data applications expand the commercial value of the platform.
The company also has relationships with Bristol Myers Squibb (BMY), Moderna (MRNA), Merck (MRK), and Recursion (RXRX). These collaborations add commercial reach across biopharma and support the data licensing narrative. Still, the stock remains a growth investment rather than a low-risk value play. Its 3.54 beta signals the potential for large price swings, while its 52-week range runs from $40.77 to $89.09.
What the TEM Rally Means for Investors After Earnings
The analyst backdrop is constructive but not without valuation tension. The consensus rating is Buy, with nine Buy ratings, five Holds, and zero Sell ratings. However, the consensus price target is $74.27, with a $75 median, $50 low, and $92 high. The $74.27 consensus sits below the $80.91 print, showing that strong sentiment does not guarantee immediate upside.
The cleanest scorecard is already defined by the quarter. Investors assessing TEM can compare future results with 23% revenue growth, 66% gross margin, 32% oncology volume growth, 33% Data & Applications growth, and $25.6M adjusted EBITDA. If those metrics hold, the growth thesis gains support. If growth or margin progress slips, the premium valuation faces more pressure.
Position sizing also matters. A 12% single-day move and a 3.54 beta create meaningful volatility even when the operating news is favorable. A disciplined approach separates the business case from the trading impulse, especially after a sharp earnings repricing.
Bottom Line for Tempus AI (TEM) After the Earnings Move
Tempus AI's 12.03% climb has a specific foundation: a strong Q3, a major adjusted EPS beat, narrower losses, and higher 2026 revenue guidance. The next phase of the investment case rests on whether Tempus can sustain its growth and profitability gains while supporting a $14.34B valuation.
TEM is up because Tempus AI reported stronger-than-expected Q3 results, including a revenue beat and adjusted EPS of $0.07 versus an expected loss. The company also raised its 2026 revenue guidance, which boosted investor confidence.
+Should I buy TEM stock now?
The earnings report is constructive, but TEM already trades at a premium and remains highly volatile. Investors should weigh the improved growth outlook against valuation risk before buying.
+Did Tempus AI beat earnings estimates?
Yes. Tempus AI beat both revenue and adjusted EPS expectations in Q3. Revenue came in at $411.5 million, and adjusted EPS was $0.07 versus a consensus estimate for a $0.09 loss.
+What does the higher 2026 guidance mean for TEM investors?
The higher 2026 revenue guidance suggests management sees continued demand and better execution ahead. That supports the growth thesis, but investors still need to watch whether Tempus can keep improving margins and profitability.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on TEM?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.